Rate of Cardiovascular Adverse Events, Myocarditis May Be Low in Trials Assessing ICIs
September 10th 2024Even with a low rates of cardiovascular adverse events in patients treated with immune checkpoint inhibitors, cancer care teams should still focus on multidisciplinary approaches and early recognition of these events.